Please Wait.....
Report
Custom Antibody Market by Service (Development, Purification, Fragmentation, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology, Infectious, CVD) - Global Forecast to 2029
Market Report I 2024-06-05 I 377 Pages I MarketsandMarkets
The custom antibody market is expected to reach USD 901 million in 2029 from USD 579 million in 2024, at a CAGR of 9.2% during the forecast period.
The growth of this market can be attributed to the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases, which has heightened the demand for targeted and effective therapeutic antibodies. Advancements in biotechnology and genetic engineering have significantly improved the development and production of custom antibodies, enhancing their specificity and efficacy.
"The antibody development segment accounted for the largest share by service in the custom antibody market 2023."
The custom antibody market by service is segmented into antibody development, antibody production & purification, and antibody fragmentation & labeling. The antibody development is further subsegmented into antigen preparation, immunization & hybridoma production, and antibody characterization. In 2023, the antibody development segment accounted for the largest share of the service segment in the global custom antibody market. Factors such as the increasing use of antibodies in drug delivery systems, such as antibody-drug conjugates (ADCs), has expanded the need for custom antibody development.
"The Asia Pacific region is growing at the highest CAGR in the custom antibody market from 2024 to 2029."
The Asia Pacific region is expected to grow at the highest growth rate during the forecast period. Various factors including emerging economies, increased prevalence of chronic diseases, and large patient pool undergoing advanced medical treatment are factors driving the high growth of the APAC market.
Increased research investments from government funding are expected to boost the growth of the custom antibody market in the Asia Pacific region. As the region continues to invest in drug development, there is a growing demand for research antibodies driving demand for custom antibodies.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: C-level Executives - 55%, Director-level - 20%, and Others - 25%
- By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin America -10%, Middle East -3%, and Africa-2%.
List of Companies Profiled in the Report:
- Thermo Fisher Scientific Inc. (US)
- GenScript (US)
- Merck KGaA (Germany)
- Bio-Rad Laboratories, Inc. (US)
- Agilent Technologies, Inc. (US)
- Revvity, Inc. (US)
- Bio-Techne (US)
- ROCKLAND IMMUNOCHEMICALS, INC. (US)
- Laboratory Corporation of America Holdings (US)
- Inotiv (US)
- Danaher Corporation (US)
- Sino Biological, Inc. (China)
- KANEKA CORPORATION (Japan)
- OriGene Technologies, Inc. (US)
- Absolute Biotech (US)
- Biointron Biologics (China)
- Cell Signaling Technology, Inc. (US)
- Curia Global, Inc. (US)
- Mabtech (Sweden)
- ACROBiosystems (US)
- Elabscience Bionovation Inc. (US)
- Creative Diagnostics (US)
- CUSABIO TECHNOLOGY LLC (US)
- BioGenes GmbH (Germany)
- RayBiotech, Inc. (US)
- Proteintech Group, Inc (US)
- IMGENEX INDIA Pvt Ltd. (India)
- Synbio Technologies (US)
- ProSci Incorporated (US)
- Creative Biolabs (US)
Research Coverage:
This research report categorizes the custom antibody market by service (antibody development (antigen preparation, immunization & hybridoma production, and antibody characterization), antibody production & purification, and antibody fragmentation & labeling, type (monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others), source (mice, rabbits, and others), application (research, and therapeutics), indication (oncology, infectious diseases, immunology, neurobiology, cardiovascular diseases, and other indications), end user (pharmaceutical & biotechnologies companies, academic & research institutes, and contract research organizations), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report provides in-depth information on significant factors influencing the growth of the custom antibody market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches, and acquisitions within the custom antibody market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall custom antibody market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (growing importance of custom antibodies in precision medicine, use of antibodies in biomarker identification and validation, rising research activities and funding investments for antibody development, advancement in biotechnology and genetic engineering), restraints (High cost and time-consuming antibody development from transgenic animals), opportunities (rising therapeutic and diagnostic application of antibodies, high scope for growth in emerging economies), and challenges (challenges associated with safety and stability) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched services of the custom antibody market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the custom antibody market
- Competitive Assessment: Thermo Fisher Scientific Inc. (US), GenScript (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Revvity, Inc. (US), Bio-Techne (US), ROCKLAND IMMUNOCHEMICALS, INC. (US), Laboratory Corporation of America Holdings (US), Inotiv (US), Danaher Corporation (US), Sino Biological, Inc. (China), KANEKA CORPORATION (Japan), OriGene Technologies, Inc. (US), Absolute Biotech (US), Biointron Biologics (China), Cell Signaling Technology, Inc. (US), Curia Global, Inc. (US), Mabtech (Sweden), ACROBiosystems (US), Elabscience Bionovation Inc. (US), Creative Diagnostics (US), CUSABIO TECHNOLOGY LLC (US), BioGenes GmbH (Germany), RayBiotech, Inc. (US), Proteintech Group, Inc (US), IMGENEX INDIA Pvt Ltd. (India), Synbio Technologies (US), ProSci Incorporated (US), Creative Biolabs (US) among others in the market.
1 INTRODUCTION 51
1.1 STUDY OBJECTIVES 51
1.2 MARKET DEFINITION 52
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY 52
1.3 MARKET SCOPE 53
1.3.1 MARKETS COVERED 53
1.3.2 REGIONS COVERED 54
1.4 YEARS CONSIDERED 54
1.5 CURRENCY CONSIDERED 55
1.6 STAKEHOLDERS 55
1.7 SUMMARY OF CHANGES 55
1.8 RECESSION IMPACT 56
2 RESEARCH METHODOLOGY 57
2.1 RESEARCH DATA 57
FIGURE 1 RESEARCH DESIGN 57
2.1.1 SECONDARY DATA 58
2.1.2 PRIMARY DATA 59
FIGURE 2 CUSTOM ANTIBODY MARKET: BREAKDOWN OF PRIMARIES 59
2.2 MARKET ESTIMATION METHODOLOGY 60
FIGURE 3 CUSTOM ANTIBODY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 60
2.2.1 MARKET ESTIMATION 60
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 61
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2023) 61
2.2.1.1 Insights of primary experts 63
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 63
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION 63
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 63
2.3 MARKET GROWTH RATE PROJECTIONS 65
FIGURE 8 CUSTOM ANTIBODY MARKET: CAGR PROJECTIONS 65
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 66
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 67
FIGURE 9 DATA TRIANGULATION METHODOLOGY 67
2.5 RESEARCH ASSUMPTIONS 68
2.6 LIMITATIONS 68
2.7 RISK ANALYSIS 69
2.8 RECESSION IMPACT ANALYSIS 69
3 EXECUTIVE SUMMARY 71
FIGURE 10 CUSTOM ANTIBODY MARKET, BY SERVICE, 2024 VS. 2029 (USD MILLION) 71
FIGURE 11 CUSTOM ANTIBODY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 72
FIGURE 12 CUSTOM ANTIBODY MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION) 72
FIGURE 13 CUSTOM ANTIBODY MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION) 73
FIGURE 14 CUSTOM ANTIBODY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 73
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF CUSTOM ANTIBODY MARKET 74
4 PREMIUM INSIGHTS 76
4.1 CUSTOM ANTIBODY MARKET OVERVIEW 76
FIGURE 16 GROWING IMPORTANCE OF CUSTOM ANTIBODIES IN PRECISION MEDICINE TO DRIVE GROWTH 76
4.2 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE AND COUNTRY (2023) 77
FIGURE 17 ANTIBODY DEVELOPMENT SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC CUSTOM ANTIBODY MARKET IN 2023 77
4.3 CUSTOM ANTIBODY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 78
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 78
4.4 CUSTOM ANTIBODY MARKET SHARE, BY END USER, 2023 78
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 78
5 MARKET OVERVIEW 79
5.1 INTRODUCTION 79
5.2 MARKET DYNAMICS 79
FIGURE 20 CUSTOM ANTIBODY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 79
TABLE 2 CUSTOM ANTIBODY MARKET: IMPACT ANALYSIS 80
5.2.1 DRIVERS 80
5.2.1.1 Growing importance of custom antibodies in precision medicine 80
5.2.1.2 Use of antibodies in biomarker identification and validation 81
5.2.1.3 Rising research activities and funding investments for antibody development 81
5.2.1.4 Advancements in biotechnology and genetic engineering 82
5.2.2 RESTRAINTS 83
5.2.2.1 High cost and time-consuming antibody development from transgenic animals 83
5.2.3 OPPORTUNITIES 83
5.2.3.1 Rising therapeutic and diagnostic application of antibodies 83
5.2.3.2 High scope for growth in emerging economies 84
5.2.4 CHALLENGES 84
5.2.4.1 Challenges associated with safety and stability 84
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 85
FIGURE 21 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 85
5.4 REGULATORY LANDSCAPE 86
5.4.1 REGULATORY SCENARIO 86
5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 4 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
5.5 VALUE CHAIN ANALYSIS 92
FIGURE 22 CUSTOM ANTIBODY MARKET: VALUE CHAIN ANALYSIS 92
5.6 TECHNOLOGICAL ANALYSIS 93
5.6.1 KEY TECHNOLOGIES 93
5.6.1.1 Hybridoma technology 93
5.6.1.2 Phage display technology 94
5.6.1.3 Recombinant DNA technology 94
5.6.2 COMPLIMENTARY TECHNOLOGIES 94
5.6.2.1 Next-generation sequencing 94
5.6.2.2 High-throughput screening 94
5.6.3 ADJACENT TECHNOLOGIES 95
5.6.3.1 Single-cell analysis technology 95
5.6.3.2 Peptide synthesis 95
5.6.3.3 Protein engineering 95
5.7 PRICING ANALYSIS 95
5.7.1 INDICATIVE PRICING ANALYSIS, BY SERVICE, 2023 & 2024 96
TABLE 7 INDICATIVE PRICE ANALYSIS, BY SERVICE, 2023 & 2024 96
5.7.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2023 & 2024 96
TABLE 8 INDICATIVE PRICE ANALYSIS, BY REGION, 2023 & 2024 96
5.8 PATENT ANALYSIS 96
5.8.1 METHODOLOGY 96
5.8.2 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024 96
TABLE 9 PATENTS FILED, 2014-2024 96
5.8.3 INNOVATION AND PATENT APPLICATIONS 97
FIGURE 23 TOTAL NUMBER OF PATENTS GRANTED, 2014-2024 97
5.8.4 TOP APPLICANTS 97
FIGURE 24 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2024 97
TABLE 10 TOP 20 PATENT OWNERS IN CUSTOM ANTIBODY MARKET, 2014-2024 98
TABLE 11 INDICATIVE LIST OF PATENTS IN CUSTOM ANTIBODY MARKET, 2022-2024 99
?
5.9 SUPPLY CHAIN ANALYSIS 100
FIGURE 25 CUSTOM ANTIBODY MARKET: SUPPLY CHAIN ANALYSIS 101
5.10 ECOSYSTEM ANALYSIS 101
FIGURE 26 CUSTOM ANTIBODY MARKET: ECOSYSTEM ANALYSIS 101
5.10.1 CUSTOM ANTIBODY RAW MATERIAL SUPPLIERS 102
TABLE 12 CUSTOM ANTIBODY MARKET: RAW MATERIAL SUPPLIERS 102
5.10.2 CUSTOM ANTIBODY SERVICE PROVIDERS 102
TABLE 13 CUSTOM ANTIBODY MARKET: SERVICE PROVIDERS 102
5.10.3 CUSTOM ANTIBODY END USERS 102
TABLE 14 CUSTOM ANTIBODY MARKET: END USERS 103
5.10.4 CUSTOM ANTIBODY REGULATORY AUTHORITIES 103
TABLE 15 CUSTOM ANTIBODY MARKET: REGULATORY AUTHORITIES 103
5.11 KEY CONFERENCES AND EVENTS, 2024-2025 104
TABLE 16 CUSTOM ANTIBODY MARKET: LIST OF CONFERENCES AND EVENTS, 2024-2025 104
5.12 PORTER'S FIVE FORCES ANALYSIS 105
FIGURE 27 CUSTOM ANTIBODY MARKET: PORTER'S FIVE FORCES ANALYSIS 105
5.12.1 IMPACT OF PORTER'S FIVE FORCES ON CUSTOM ANTIBODY MARKET 105
TABLE 17 CUSTOM ANTIBODY MARKET: PORTER'S FIVE FORCES ANALYSIS 105
5.12.2 INTENSITY OF COMPETITIVE RIVALRY 106
5.12.3 BARGAINING POWER OF SUPPLIERS 106
5.12.4 BARGAINING POWER OF BUYERS 106
5.12.5 THREAT OF SUBSTITUTES 106
5.12.6 THREAT OF NEW ENTRANTS 106
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 107
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 107
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CUSTOM ANTIBODIES 107
5.13.2 CUSTOM ANTIBODY MARKET: BUYING CRITERIA FOR END USERS 108
FIGURE 29 KEY BUYING CRITERIA FOR END USERS OF CUSTOM ANTIBODIES 108
TABLE 18 BUYING CRITERIA FOR CUSTOM ANTIBODIES, BY END USER 108
5.14 INVESTMENT AND FUNDING SCENARIO 109
TABLE 19 RESEARCH FUNDING BY VARIOUS INSTITUTES/CENTERS, 2020-2024 (USD MILLION) 109
6 CUSTOM ANTIBODY MARKET, BY SERVICE 110
6.1 INTRODUCTION 111
TABLE 20 CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 111
6.2 ANTIBODY DEVELOPMENT 111
TABLE 21 CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 112
TABLE 22 CUSTOM ANTIBODY DEVELOPMENT MARKET, BY REGION, 2022-2029 (USD MILLION) 112
TABLE 23 NORTH AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 113
TABLE 24 EUROPE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 113
TABLE 25 ASIA PACIFIC: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 114
TABLE 26 LATIN AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 114
TABLE 27 MIDDLE EAST: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 115
TABLE 28 GCC COUNTRIES: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 115
6.2.1 ANTIBODY CHARACTERIZATION 115
6.2.1.1 Growing adoption of therapeutic antibodies to drive growth 115
TABLE 29 ANTIBODY CHARACTERIZATION MARKET, BY REGION, 2022-2029 (USD MILLION) 116
TABLE 30 NORTH AMERICA: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 116
TABLE 31 EUROPE: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 117
TABLE 32 ASIA PACIFIC: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 117
TABLE 33 LATIN AMERICA: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 118
TABLE 34 MIDDLE EAST: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 118
TABLE 35 GCC COUNTRIES: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 118
6.2.2 ANTIGEN PREPARATION 119
6.2.2.1 Rising use of research antibodies to support market growth 119
TABLE 36 ANTIGEN PREPARATION MARKET, BY REGION, 2022-2029 (USD MILLION) 120
TABLE 37 NORTH AMERICA: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 120
TABLE 38 EUROPE: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 121
TABLE 39 ASIA PACIFIC: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 121
TABLE 40 LATIN AMERICA: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 122
TABLE 41 MIDDLE EAST: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 122
TABLE 42 GCC COUNTRIES: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 122
6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION 123
6.2.3.1 Rising demand for therapeutic antibodies to drive market 123
TABLE 43 IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY REGION, 2022-2029 (USD MILLION) 123
TABLE 44 NORTH AMERICA: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 124
TABLE 45 EUROPE: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 124
TABLE 46 ASIA PACIFIC: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 125
TABLE 47 LATIN AMERICA: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 125
TABLE 48 MIDDLE EAST: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 126
TABLE 49 GCC COUNTRIES: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 126
6.3 ANTIBODY PRODUCTION & PURIFICATION 126
6.3.1 RESEARCH & DEVELOPMENT IN LIFE SCIENCES TO BOOST MARKET GROWTH 126
TABLE 50 CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY REGION, 2022-2029 (USD MILLION) 127
TABLE 51 NORTH AMERICA: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 127
TABLE 52 EUROPE: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 128
TABLE 53 ASIA PACIFIC: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 128
TABLE 54 LATIN AMERICA: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 55 MIDDLE EAST: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 56 GCC COUNTRIES: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 129
6.4 ANTIBODY FRAGMENTATION & LABELING 130
6.4.1 RISING RESEARCH AND CLINICAL APPLICATIONS TO DRIVE GROWTH 130
TABLE 57 CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY REGION, 2022-2029 (USD MILLION) 131
TABLE 58 NORTH AMERICA: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 131
TABLE 59 EUROPE: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 132
TABLE 60 ASIA PACIFIC: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 132
TABLE 61 LATIN AMERICA: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 133
TABLE 62 MIDDLE EAST: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 133
TABLE 63 GCC COUNTRIES: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 133
7 CUSTOM ANTIBODY MARKET, BY TYPE 134
7.1 INTRODUCTION 135
TABLE 64 CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 135
7.2 MONOCLONAL ANTIBODIES 135
7.2.1 HIGH DEGREE OF SENSITIVITY AND PRECISION TO BOOST MARKET GROWTH 135
TABLE 65 CUSTOM MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION) 136
TABLE 66 NORTH AMERICA: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 136
TABLE 67 EUROPE: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 137
TABLE 68 ASIA PACIFIC: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 137
TABLE 69 LATIN AMERICA: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 138
TABLE 70 MIDDLE EAST: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 138
TABLE 71 GCC COUNTRIES: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 138
7.3 POLYCLONAL ANTIBODIES 139
7.3.1 VERSATILITY AND EFFICACY IN RECOGNITION OF ANTIGEN SITES TO BOOST MARKET GROWTH 139
TABLE 72 CUSTOM POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION) 140
TABLE 73 NORTH AMERICA: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 140
TABLE 74 EUROPE: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 141
TABLE 75 ASIA PACIFIC: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 141
TABLE 76 LATIN AMERICA: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 142
TABLE 77 MIDDLE EAST: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 142
TABLE 78 GCC COUNTRIES: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 142
7.4 RECOMBINANT ANTIBODIES 143
7.4.1 RISING RESEARCH & DEVELOPMENT IN LIFE SCIENCES INDUSTRY TO BOOST MARKET GROWTH 143
TABLE 79 CUSTOM RECOMBINANT ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION) 144
TABLE 80 NORTH AMERICA: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 144
TABLE 81 EUROPE: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 145
TABLE 82 ASIA PACIFIC: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 145
TABLE 83 LATIN AMERICA: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 146
TABLE 84 MIDDLE EAST: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 146
TABLE 85 GCC COUNTRIES: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 146
7.5 OTHER CUSTOM ANTIBODIES 147
TABLE 86 OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION) 147
TABLE 87 NORTH AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 148
TABLE 88 EUROPE: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 148
TABLE 89 ASIA PACIFIC: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 149
TABLE 90 LATIN AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 149
TABLE 91 MIDDLE EAST: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 150
TABLE 92 GCC COUNTRIES: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 150
8 CUSTOM ANTIBODY MARKET, BY SOURCE 151
8.1 INTRODUCTION 152
TABLE 93 CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 152
8.2 MICE 152
8.2.1 WIDESPREAD AVAILABILITY AND COST-EFFECTIVENESS TO PROPEL MARKET 152
TABLE 94 CUSTOM ANTIBODY MARKET FOR MICE, BY REGION, 2022-2029 (USD MILLION) 153
TABLE 95 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION) 153
TABLE 96 EUROPE: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION) 154
TABLE 97 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION) 154
TABLE 98 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION) 155
TABLE 99 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION) 155
TABLE 100 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION) 155
8.3 RABBITS 156
8.3.1 ABILITY TO GENERATE HIGH ANTIBODY DIVERSITY WITH OPTIMAL AFFINITY TO DRIVE MARKET 156
TABLE 101 CUSTOM ANTIBODY MARKET FOR RABBITS, BY REGION, 2022-2029 (USD MILLION) 156
TABLE 102 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION) 157
TABLE 103 EUROPE: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION) 157
TABLE 104 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION) 158
TABLE 105 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION) 158
TABLE 106 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION) 159
TABLE 107 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION) 159
8.4 OTHER SOURCES 159
TABLE 108 CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY REGION, 2022-2029 (USD MILLION) 160
TABLE 109 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION) 161
TABLE 110 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION) 161
TABLE 111 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION) 162
TABLE 112 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION) 162
TABLE 113 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION) 162
TABLE 114 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION) 163
9 CUSTOM ANTIBODY MARKET, BY APPLICATION 164
9.1 INTRODUCTION 165
TABLE 115 CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 165
9.2 RESEARCH 165
9.2.1 HIGH DEGREE OF SENSITIVITY AND SPECIFICITY TO BOOST MARKET GROWTH 165
TABLE 116 CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 166
TABLE 117 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 166
TABLE 118 EUROPE: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 167
TABLE 119 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 167
TABLE 120 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 168
TABLE 121 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 168
TABLE 122 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 168
9.3 THERAPEUTIC 169
9.3.1 RISING DEMAND FOR ANTIBODY-BASED THERAPEUTICS TO SUPPORT MARKET GROWTH 169
TABLE 123 CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION) 169
TABLE 124 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 170
TABLE 125 EUROPE: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 170
TABLE 126 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 171
TABLE 127 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 171
TABLE 128 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 172
TABLE 129 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 172
10 CUSTOM ANTIBODY MARKET, BY INDICATION 173
10.1 INTRODUCTION 174
TABLE 130 CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 174
10.2 ONCOLOGY 174
10.2.1 RISING PREVALENCE OF CANCER TO DRIVE MARKET 174
TABLE 131 CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD MILLION) 175
TABLE 132 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 175
TABLE 133 EUROPE: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 176
TABLE 134 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 176
TABLE 135 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 177
TABLE 136 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 177
TABLE 137 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 177
10.3 INFECTIOUS DISEASES 178
10.3.1 USE OF ANTIBODIES IN VACCINE & THERAPEUTIC DEVELOPMENT TO BOOST MARKET GROWTH 178
TABLE 138 CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION) 178
TABLE 139 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 179
TABLE 140 EUROPE: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 179
TABLE 141 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 180
TABLE 142 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 180
TABLE 143 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 181
TABLE 144 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 181
?
10.4 IMMUNOLOGY 181
10.4.1 RISING NUMBER OF PRODUCTS UNDER CLINICAL STUDIES TO BOOST MARKET GROWTH 181
TABLE 145 CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY REGION, 2022-2029 (USD MILLION) 182
TABLE 146 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 183
TABLE 147 EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 183
TABLE 148 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 184
TABLE 149 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 184
TABLE 150 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 185
TABLE 151 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 185
10.5 NEUROBIOLOGY 185
10.5.1 RISING DEMAND FOR ANTIBODIES IN NEURODEGENERATIVE DISEASES TO PROPEL MARKET 185
TABLE 152 CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY REGION, 2022-2029 (USD MILLION) 186
TABLE 153 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 186
TABLE 154 EUROPE: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 187
TABLE 155 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 187
TABLE 156 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 188
TABLE 157 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 188
TABLE 158 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 188
10.6 CARDIOVASCULAR DISEASES 189
10.6.1 RISING DEMAND FOR CVD BIOMARKERS TO DRIVE MARKET 189
TABLE 159 CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD MILLION) 189
TABLE 160 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 190
TABLE 161 EUROPE: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 190
TABLE 162 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 191
TABLE 163 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 191
TABLE 164 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 192
TABLE 165 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 192
10.7 OTHER INDICATIONS 192
TABLE 166 CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2029 (USD MILLION) 193
TABLE 167 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 194
TABLE 168 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 194
TABLE 169 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 195
TABLE 170 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 195
TABLE 171 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 196
TABLE 172 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 196
11 CUSTOM ANTIBODY MARKET, BY END USER 197
11.1 INTRODUCTION 198
TABLE 173 CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 198
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 198
11.2.1 RISING DEMAND FOR THERAPEUTIC ANTIBODIES TO BOOST MARKET GROWTH 198
TABLE 174 CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION) 199
TABLE 175 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 199
TABLE 176 EUROPE: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 200
TABLE 177 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 200
TABLE 178 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 201
TABLE 179 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 201
TABLE 180 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 201
11.3 ACADEMIC & RESEARCH INSTITUTES 202
11.3.1 GROWING INDUSTRY-ACADEMIA COLLABORATIONS TO DRIVE MARKET 202
TABLE 181 CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION) 202
TABLE 182 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 203
TABLE 183 EUROPE: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 203
TABLE 184 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 204
TABLE 185 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 204
TABLE 186 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 205
TABLE 187 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 205
11.4 CONTRACT RESEARCH ORGANIZATIONS 205
11.4.1 INCREASING DEMAND FOR MABS AND ADC SERVICES TO PROPEL MARKET 205
TABLE 188 CUSTOM ANTIBODY MARKET FOR CROS, BY REGION, 2022-2029 (USD MILLION) 206
TABLE 189 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION) 206
TABLE 190 EUROPE: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION) 207
TABLE 191 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION) 207
TABLE 192 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION) 208
TABLE 193 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION) 208
TABLE 194 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION) 208
12 CUSTOM ANTIBODY MARKET, BY REGION 209
12.1 INTRODUCTION 210
TABLE 195 CUSTOM ANTIBODY MARKET, BY REGION, 2022-2029 (USD MILLION) 210
12.2 NORTH AMERICA 210
FIGURE 30 NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT 211
TABLE 196 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 212
TABLE 197 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 212
TABLE 198 NORTH AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 212
TABLE 199 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 213
TABLE 200 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 213
TABLE 201 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 213
TABLE 202 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 214
TABLE 203 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 214
12.2.1 US 214
12.2.1.1 Growing number of FDA approvals for monoclonal antibody therapies to drive market 214
FIGURE 31 NIH FUNDING IN LAST 10 YEARS FOR HEALTHCARE R&D (2014-2024) 215
TABLE 204 US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 216
TABLE 205 US: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 216
TABLE 206 US: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 216
TABLE 207 US: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 217
TABLE 208 US: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 217
TABLE 209 US: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 217
TABLE 210 US: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 218
12.2.2 CANADA 218
12.2.2.1 Increasing incidence of cancer to support market growth 218
TABLE 211 CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 219
TABLE 212 CANADA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 219
TABLE 213 CANADA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 220
TABLE 214 CANADA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 220
TABLE 215 CANADA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 220
TABLE 216 CANADA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 221
TABLE 217 CANADA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 221
12.2.3 NORTH AMERICA: RECESSION IMPACT 221
12.3 EUROPE 222
TABLE 218 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 222
TABLE 219 EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 223
TABLE 220 EUROPE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 223
TABLE 221 EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 224
TABLE 222 EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 224
TABLE 223 EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 224
TABLE 224 EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 225
TABLE 225 EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 225
12.3.1 GERMANY 225
12.3.1.1 Growing investment in ADCs development to drive market 225
TABLE 226 GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 226
TABLE 227 GERMANY: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 226
TABLE 228 GERMANY: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 227
TABLE 229 GERMANY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 227
TABLE 230 GERMANY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 227
TABLE 231 GERMANY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 228
TABLE 232 GERMANY: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 228
12.3.2 UK 228
12.3.2.1 Life sciences funding with biotech firms to boost adoption of custom antibodies 228
TABLE 233 UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 229
TABLE 234 UK: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 229
TABLE 235 UK: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 230
TABLE 236 UK CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 230
TABLE 237 UK: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 230
TABLE 238 UK: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 231
TABLE 239 UK: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 231
12.3.3 FRANCE 231
12.3.3.1 Increasing government investments in pharmaceutical industry to drive growth 231
TABLE 240 FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 232
TABLE 241 FRANCE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 233
TABLE 242 FRANCE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 233
TABLE 243 FRANCE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 233
TABLE 244 FRANCE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 234
TABLE 245 FRANCE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 234
TABLE 246 FRANCE: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 234
12.3.4 ITALY 235
12.3.4.1 Rising research activities in pharma R&D to boost market growth 235
TABLE 247 ITALY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 235
TABLE 248 ITALY: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 236
TABLE 249 ITALY: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 236
TABLE 250 ITALY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 236
TABLE 251 ITALY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 237
TABLE 252 ITALY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 237
TABLE 253 ITALY: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 237
12.3.5 SPAIN 238
12.3.5.1 Growing focus on advancements in personalized medicine to support market growth 238
TABLE 254 SPAIN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 239
TABLE 255 SPAIN: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 239
TABLE 256 SPAIN: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 240
TABLE 257 SPAIN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 240
TABLE 258 SPAIN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 240
TABLE 259 SPAIN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 241
TABLE 260 SPAIN: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 241
12.3.6 REST OF EUROPE 241
TABLE 261 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 242
TABLE 262 REST OF EUROPE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 243
TABLE 263 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 243
TABLE 264 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 243
TABLE 265 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 244
TABLE 266 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 244
TABLE 267 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 245
12.3.7 EUROPE: RECESSION IMPACT 245
12.4 ASIA PACIFIC 245
FIGURE 32 ASIA PACIFIC: CUSTOM ANTIBODY MARKET SNAPSHOT 246
TABLE 268 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 247
TABLE 269 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 247
TABLE 270 ASIA PACIFIC: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 248
TABLE 271 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 248
TABLE 272 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 248
TABLE 273 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 249
TABLE 274 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 249
TABLE 275 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 249
12.4.1 CHINA 250
12.4.1.1 Rising prevalence of cardiovascular diseases and cancer to support market growth 250
TABLE 276 CHINA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 250
TABLE 277 CHINA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 251
TABLE 278 CHINA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 251
TABLE 279 CHINA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 251
TABLE 280 CHINA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 252
TABLE 281 CHINA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 252
TABLE 282 CHINA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 252
12.4.2 JAPAN 253
12.4.2.1 Increasing research activities for development of ADCs to drive market 253
TABLE 283 JAPAN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 253
TABLE 284 JAPAN: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 254
TABLE 285 JAPAN: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 254
TABLE 286 JAPAN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 254
TABLE 287 JAPAN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 255
TABLE 288 JAPAN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 255
TABLE 289 JAPAN: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 255
12.4.3 INDIA 256
12.4.3.1 Favorable scenario for foreign direct investment to propel market 256
TABLE 290 INDIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 256
TABLE 291 INDIA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 257
TABLE 292 INDIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 257
TABLE 293 INDIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 257
TABLE 294 INDIA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 258
TABLE 295 INDIA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 258
TABLE 296 INDIA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 258
12.4.4 SOUTH KOREA 259
12.4.4.1 Increased research & development of drugs to support market growth 259
TABLE 297 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 259
TABLE 298 SOUTH KOREA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 260
TABLE 299 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 260
TABLE 300 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 260
TABLE 301 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 261
TABLE 302 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 261
TABLE 303 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 261
12.4.5 AUSTRALIA 262
12.4.5.1 Increasing demand for innovative research solutions to propel market 262
TABLE 304 AUSTRALIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 263
TABLE 305 AUSTRALIA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 263
TABLE 306 AUSTRALIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 264
TABLE 307 AUSTRALIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 264
TABLE 308 AUSTRALIA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 264
TABLE 309 AUSTRALIA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 265
TABLE 310 AUSTRALIA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 265
12.4.6 REST OF ASIA PACIFIC 265
TABLE 311 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 266
TABLE 312 REST OF ASIA PACIFIC: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 267
TABLE 313 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 267
TABLE 314 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 268
TABLE 315 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 268
TABLE 316 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 269
TABLE 317 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 269
12.4.7 ASIA PACIFIC: RECESSION IMPACT 269
12.5 LATIN AMERICA 270
TABLE 318 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 270
TABLE 319 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 271
TABLE 320 LATIN AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 271
TABLE 321 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 272
TABLE 322 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 272
TABLE 323 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 272
TABLE 324 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 273
TABLE 325 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 273
12.5.1 BRAZIL 273
12.5.1.1 Increased government investments in pharmaceutical R&D to drive market 273
TABLE 326 BRAZIL: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 274
TABLE 327 BRAZIL: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 274
TABLE 328 BRAZIL: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 275
TABLE 329 BRAZIL: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 275
TABLE 330 BRAZIL: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 275
TABLE 331 BRAZIL: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 276
TABLE 332 BRAZIL: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 276
12.5.2 MEXICO 276
12.5.2.1 Rising demand for chronic disease treatment to support market growth 276
TABLE 333 MEXICO: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 277
TABLE 334 MEXICO: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 277
TABLE 335 MEXICO: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 278
TABLE 336 MEXICO: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 278
TABLE 337 MEXICO: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 278
TABLE 338 MEXICO: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 279
TABLE 339 MEXICO: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 279
12.5.3 REST OF LATIN AMERICA 279
TABLE 340 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 280
TABLE 341 REST OF LATIN AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 280
TABLE 342 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 281
TABLE 343 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 281
TABLE 344 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 281
TABLE 345 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 282
TABLE 346 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 282
12.5.4 LATIN AMERICA: RECESSION IMPACT 282
12.6 MIDDLE EAST 283
TABLE 347 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 283
TABLE 348 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 283
TABLE 349 MIDDLE EAST: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 284
TABLE 350 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 284
TABLE 351 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 284
TABLE 352 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 285
TABLE 353 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 285
TABLE 354 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 285
12.6.1 GCC COUNTRIES 286
TABLE 355 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 286
TABLE 356 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 286
TABLE 357 GCC COUNTRIES: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 287
TABLE 358 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 287
TABLE 359 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 287
TABLE 360 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 288
TABLE 361 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 288
TABLE 362 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 289
12.6.1.1 Saudi Arabia 289
12.6.1.1.1 Growing healthcare expenditure to boost market growth 289
TABLE 363 SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 290
TABLE 364 SAUDI ARABIA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 290
TABLE 365 SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 291
TABLE 366 SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 291
TABLE 367 SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 291
TABLE 368 SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 292
TABLE 369 SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 292
12.6.1.2 UAE 292
12.6.1.2.1 Rising government funding to propel market 292
TABLE 370 UAE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 293
TABLE 371 UAE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 293
TABLE 372 UAE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 294
TABLE 373 UAE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 294
TABLE 374 UAE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 294
TABLE 375 UAE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 295
TABLE 376 UAE: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 295
12.6.1.3 Rest of GCC countries 295
TABLE 377 REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 296
TABLE 378 REST OF GCC COUNTRIES: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 297
TABLE 379 REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 297
TABLE 380 REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 298
TABLE 381 REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 298
TABLE 382 REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 299
TABLE 383 REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 299
12.6.2 REST OF MIDDLE EAST 299
TABLE 384 REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 301
TABLE 385 REST OF MIDDLE EAST: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 301
TABLE 386 REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 302
TABLE 387 REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 302
TABLE 388 REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 302
TABLE 389 REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 303
TABLE 390 REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 303
12.6.3 MIDDLE EAST: RECESSION IMPACT 303
12.7 AFRICA 304
12.7.1 GROWING MARKET FOR PHARMACEUTICALS AND INCREASING DEMAND FOR DRUGS TO SUPPORT MARKET GROWTH 304
TABLE 391 AFRICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION) 304
TABLE 392 AFRICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 305
TABLE 393 AFRICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION) 305
TABLE 394 AFRICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION) 305
TABLE 395 AFRICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 306
TABLE 396 AFRICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION) 306
TABLE 397 AFRICA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION) 306
13 COMPETITIVE LANDSCAPE 308
13.1 INTRODUCTION 308
13.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 308
TABLE 398 OVERVIEW OF STRATEGIES ADOPTED BY KEY CUSTOM ANTIBODY COMPANIES 308
13.3 REVENUE ANALYSIS 310
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN CUSTOM ANTIBODY MARKET, 2019-2023 (USD BILLION) 310
13.4 MARKET SHARE ANALYSIS 311
FIGURE 34 CUSTOM ANTIBODY MARKET SHARE ANALYSIS, BY KEY PLAYER (2023) 311
TABLE 399 CUSTOM ANTIBODY MARKET: DEGREE OF COMPETITION 311
13.5 BRAND/SERVICE COMPARATIVE ANALYSIS 313
FIGURE 35 BRAND/SERVICE COMPARATIVE ANALYSIS 313
13.5.1 THERMO FISHER SCIENTIFIC INC. 314
13.5.2 GENSCRIPT 314
13.5.3 BIO-RAD LABORATORIES, INC. 314
13.5.4 MERCK KGAA 314
13.5.5 AGILENT TECHNOLOGIES, INC. 314
13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 314
13.6.1 STARS 315
13.6.2 EMERGING LEADERS 315
13.6.3 PERVASIVE PLAYERS 315
13.6.4 PARTICIPANTS 315
FIGURE 36 CUSTOM ANTIBODY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 316
13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 317
FIGURE 37 CUSTOM ANTIBODY MARKET: COMPANY FOOTPRINT 317
TABLE 400 CUSTOM ANTIBODY MARKET: REGION FOOTPRINT 318
TABLE 401 CUSTOM ANTIBODY MARKET: SERVICE FOOTPRINT 319
TABLE 402 CUSTOM ANTIBODY MARKET: TYPE FOOTPRINT 320
TABLE 403 CUSTOM ANTIBODY MARKET: APPLICATION FOOTPRINT 321
TABLE 404 CUSTOM ANTIBODY MARKET: INDICATION FOOTPRINT 322
13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 323
13.7.1 PROGRESSIVE COMPANIES 323
13.7.2 RESPONSIVE COMPANIES 323
13.7.3 DYNAMIC COMPANIES 323
13.7.4 STARTING BLOCKS 323
FIGURE 38 CUSTOM ANTIBODY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 324
13.7.5 COMPETITIVE BENCHMARKING 325
TABLE 405 CUSTOM ANTIBODY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 325
TABLE 406 CUSTOM ANTIBODY MARKET: COMPANY FOOTPRINT (STARTUPS/SMES) 326
13.8 VALUATION AND FINANCIAL METRICS OF CUSTOM ANTIBODY SERVICE VENDORS 326
FIGURE 39 EV/EBITDA OF KEY VENDORS 326
FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 327
13.9 COMPETITIVE SCENARIO 327
13.9.1 DEALS 327
TABLE 407 CUSTOM ANTIBODY MARKET: DEALS, JANUARY 2021-APRIL 2024 327
13.9.2 EXPANSIONS 328
TABLE 408 CUSTOM ANTIBODY MARKET: EXPANSIONS, JANUARY 2021-APRIL 2024 328
14 COMPANY PROFILES 329
14.1 KEY PLAYERS 329
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 THERMO FISHER SCIENTIFIC INC. 329
TABLE 409 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 329
FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 330
TABLE 410 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 330
TABLE 411 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-APRIL 2024 332
14.1.2 GENSCRIPT 333
TABLE 412 GENSCRIPT: COMPANY OVERVIEW 333
FIGURE 42 GENSCRIPT: COMPANY SNAPSHOT (2023) 334
TABLE 413 GENSCRIPT: SERVICES OFFERED 334
TABLE 414 GENSCRIPT: DEALS, JANUARY 2021-APRIL 2024 335
TABLE 415 GENSCRIPT: EXPANSIONS, JANUARY 2021-APRIL 2024 336
14.1.3 BIO-RAD LABORATORIES, INC. 337
TABLE 416 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 337
FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 338
TABLE 417 BIO-RAD LABORATORIES, INC.: SERVICES OFFERED 338
TABLE 418 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES,
JANUARY 2021-APRIL 2024 339
14.1.4 MERCK KGAA 340
TABLE 419 MERCK KGAA: COMPANY OVERVIEW 340
FIGURE 44 MERCK KGAA: COMPANY SNAPSHOT (2023) 341
TABLE 420 MERCK KGAA: SERVICES OFFERED 341
TABLE 421 MERCK KGAA: DEALS, JANUARY 2021-APRIL 2024 342
TABLE 422 MERCK KGAA: EXPANSIONS, JANUARY 2021-APRIL 2024 342
14.1.5 AGILENT TECHNOLOGIES, INC. 343
TABLE 423 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 343
FIGURE 45 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) 344
TABLE 424 AGILENT TECHNOLOGIES, INC.: SERVICES OFFERED 344
14.1.6 REVVITY, INC. 345
TABLE 425 REVVITY, INC.: COMPANY OVERVIEW 345
FIGURE 46 REVVITY, INC.: COMPANY SNAPSHOT (2023) 346
TABLE 426 REVVITY, INC.: SERVICES OFFERED 347
TABLE 427 REVVITY, INC.: DEALS, JANUARY 2021-APRIL 2024 347
14.1.7 BIO-TECHNE 348
TABLE 428 BIO-TECHNE: COMPANY OVERVIEW 348
FIGURE 47 BIO-TECHNE: COMPANY SNAPSHOT (2023) 349
TABLE 429 BIO-TECHNE: SERVICES OFFERED 349
TABLE 430 BIO-TECHNE: DEALS, JANUARY 2021-APRIL 2024 350
14.1.8 ROCKLAND IMMUNOCHEMICALS, INC. 351
TABLE 431 ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW 351
TABLE 432 ROCKLAND IMMUNOCHEMICALS, INC.: SERVICES OFFERED 351
TABLE 433 ROCKLAND IMMUNOCHEMICALS, INC.: DEALS, JANUARY 2021-APRIL 2024 352
14.1.9 LABORATORY CORPORATION OF AMERICA HOLDINGS 353
TABLE 434 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW 353
FIGURE 48 LABORATORY CORPORATION OF AMERICA HOLDINGS:
COMPANY SNAPSHOT (2023) 354
TABLE 435 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED 355
14.1.10 INOTIV 356
TABLE 436 INOTIV: COMPANY OVERVIEW 356
FIGURE 49 INOTIV.: COMPANY SNAPSHOT (2023) 357
TABLE 437 INOTIV: SERVICES OFFERED 357
TABLE 438 INOTIV: DEALS, JANUARY 2021-APRIL 2024 358
TABLE 439 INOTIV: EXPANSIONS, JANUARY 2021-APRIL 2024 358
14.1.11 DANAHER CORPORATION 359
TABLE 440 DANAHER CORPORATION: COMPANY OVERVIEW 359
FIGURE 50 DANAHER CORPORATION: COMPANY SNAPSHOT (2023) 360
TABLE 441 DANAHER CORPORATION: SERVICES OFFERED 361
TABLE 442 DANAHER CORPORATION: DEALS, JANUARY 2021-APRIL 2024 362
TABLE 443 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021-APRIL 2024 362
14.1.12 SINO BIOLOGICAL, INC. 363
TABLE 444 SINO BIOLOGICAL, INC.: COMPANY OVERVIEW 363
FIGURE 51 SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT (2023) 363
TABLE 445 SINO BIOLOGICAL, INC.: SERVICES OFFERED 364
TABLE 446 SINO BIOLOGICAL, INC.: DEALS, JANUARY 2021-APRIL 2024 365
TABLE 447 SINO BIOLOGICAL, INC.: EXPANSIONS, JANUARY 2021-APRIL 2024 365
14.1.13 KANEKA CORPORATION 366
TABLE 448 KANEKA CORPORATION: COMPANY OVERVIEW 366
FIGURE 52 KANEKA CORPORATION: COMPANY SNAPSHOT (2022) 367
TABLE 449 KANEKA CORPORATION: SERVICES OFFERED 367
14.1.14 ORIGENE TECHNOLOGIES, INC. 368
TABLE 450 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW 368
TABLE 451 ORIGENE TECHNOLOGIES, INC.: SERVICES OFFERED 368
14.1.15 ABSOLUTE BIOTECH 369
TABLE 452 ABSOLUTE BIOTECH: COMPANY OVERVIEW 369
TABLE 453 ABSOLUTE BIOTECH: SERVICES OFFERED 369
TABLE 454 ABSOLUTE BIOTECH: DEALS, JANUARY 2021-APRIL 2024 370
TABLE 455 ABSOLUTE BIOTECH: EXPANSIONS, JANUARY 2021-APRIL 2024 370
14.1.16 BIOINTRON BIOLOGICS 371
TABLE 456 BIONTRON BIOLOGICS: COMPANY OVERVIEW 371
TABLE 457 BIOINTRON BIOLOGICS: SERVICES OFFERED 371
TABLE 458 BIOINTRON BIOLOGICS: DEALS, JANUARY 2021-APRIL 2024 372
14.2 OTHER PLAYERS 373
14.2.1 CELL SIGNALING TECHNOLOGY, INC. 373
TABLE 459 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW 373
14.2.2 CURIA GLOBAL, INC. 374
TABLE 460 CURIA GLOBAL, INC.: COMPANY OVERVIEW 374
14.2.3 MABTECH 375
TABLE 461 MABTECH: COMPANY OVERVIEW 375
14.2.4 ACROBIOSYSTEMS 376
TABLE 462 ACROBIOSYSTEMS: COMPANY OVERVIEW 376
14.2.5 ELABSCIENCE BIONOVATION INC. 377
TABLE 463 ELABSCIENCE BIONOVATION INC.: COMPANY OVERVIEW 377
14.2.6 CREATIVE DIAGNOSTICS 378
TABLE 464 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW 378
14.2.7 CUSABIO TECHNOLOGY LLC 379
TABLE 465 CUSABIO TECHNOLOGY LLC: COMPANY OVERVIEW 379
14.2.8 BIOGENES GMBH 380
TABLE 466 BIOGENES GMBH: COMPANY OVERVIEW 380
14.2.9 RAYBIOTECH, INC. 381
TABLE 467 RAYBIOTECH, INC.: COMPANY OVERVIEW 381
14.2.10 PROTEINTECH GROUP, INC. 382
TABLE 468 PROTEINTECH GROUP, INC.: COMPANY OVERVIEW 382
14.2.11 IMGENEX INDIA PVT. LTD. 383
TABLE 469 IMGENEX INDIA PVT. LTD.: COMPANY OVERVIEW 383
14.2.12 SYNBIO TECHNOLOGIES 384
TABLE 470 SYNBIO TECHNOLOGIES: COMPANY OVERVIEW 384
14.2.13 PROSCI INCORPORATED 385
TABLE 471 PROSCI INCORPORATED: COMPANY OVERVIEW 385
14.2.14 CREATIVE BIOLABS 386
TABLE 472 CREATIVE BIOLABS: COMPANY OVERVIEW 386
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX 387
15.1 DISCUSSION GUIDE 387
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 391
15.3 CUSTOMIZATION OPTIONS 393
15.4 RELATED REPORTS 394
15.5 AUTHOR DETAILS 395
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security